TELA Bio, Inc.: diluted weighted-average shares
Diluted weighted-average shares for TELA Bio, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All TELA Bio, Inc. financial histories
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Reading these values
This selected numerical history matches Basic weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Context from the filing
For TELA Bio in 2023–2025, basic and diluted loss per share use the same denominator because additional potential shares would be anti-dilutive. Outstanding pre-funded warrants with a $0.0001 exercise price are already included in weighted-average common shares from their respective closing dates; they are not added again. Full share counts follow the statement’s share/per-share exception to its thousands heading. EPS uses net loss, which is distinct from comprehensive loss after foreign-currency translation adjustments. Read the source filing.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 46,947,932 | shares | 2026-03-25 | 10-K · 0001104659-26-034507 |
| 2024-01-01 | 2024-12-31 | 28,526,441 | shares | 2026-03-25 | 10-K · 0001104659-26-034507 |
| 2023-01-01 | 2023-12-31 | 22,868,663 | shares | 2026-03-25 | 10-K · 0001104659-26-034507 |
| 2022-01-01 | 2022-12-31 | 16,267,678 | shares | 2025-03-21 | 10-K · 0001558370-25-003460 |
| 2021-01-01 | 2021-12-31 | 14,473,213 | shares | 2024-03-22 | 10-K · 0001558370-24-003782 |
| 2020-01-01 | 2020-12-31 | 12,934,421 | shares | 2023-03-23 | 10-K · 0001558370-23-004468 |
| 2019-01-01 | 2019-12-31 | 1,766,412 | shares | 2022-03-23 | 10-K · 0001558370-22-004151 |
Related financial histories
- TELA Bio, Inc.: total assets
- TELA Bio, Inc.: total liabilities
- TELA Bio, Inc.: stockholders equity
- TELA Bio, Inc.: cash and cash equivalents
- TELA Bio, Inc.: net income or loss
- TELA Bio, Inc.: operating cash flow
- TELA Bio, Inc.: capital expenditure payments
- TELA Bio, Inc.: contract revenue excluding tax
- TELA Bio, Inc.: financing cash flow
- TELA Bio, Inc.: investing cash flow
- TELA Bio, Inc.: retained earnings or deficit
- TELA Bio, Inc.: basic weighted-average shares
- TELA Bio, Inc.: basic earnings per share
- TELA Bio, Inc.: diluted earnings per share
- TELA Bio, Inc.: net property, plant and equipment
- TELA Bio, Inc.: share-based compensation expense
- TELA Bio, Inc.: operating income or loss
- TELA Bio, Inc.: current assets
- TELA Bio, Inc.: interest expense
- TELA Bio, Inc.: current liabilities
- TELA Bio, Inc.: current accounts payable
- TELA Bio, Inc.: operating expenses
- TELA Bio, Inc.: net inventory
- TELA Bio, Inc.: gross profit
- TELA Bio, Inc.: research and development expense
Inspect the source
- Entity
- TELA Bio, Inc. / CIK 0001561921
- Captured
- 2026-09-20T09:19:53.840Z
- SEC response SHA-256
5b3bce53267a4a1e1ea2217ff00651e3fbd53c3402119ff3ea6d12b29bf3f160
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001561921.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))